The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula ##STR00001## a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C.sub.1-10alkanediyl; R.sup.1 is Ar.sup.1 or a monocyclic or bicyclic heterocycle Q is R.sup.7, pyrrolidinyl substituted with R.sup.7, piperidinyl substituted with R.sup.7 or homopiperidinyl substituted with R.sup.7; one of R.sup.2a and R.sup.3a is selected from halo, optionally mono- or polysubstituted C.sub.1-6alkyl, optionally mono- or polysubstituted C.sub.2-6alkenyl, nitro, hydroxy, Ar.sup.2, N(R.sup.4aR.sup.4b), N(R.sup.4aR.sup.4b)sulfonyl, N(R.sup.4aR.sup.4b)carbonyl, C.sub.1-6alkyloxy, Ar.sup.2oxy, Ar.sup.2C.sub.1-6alkyloxy, carboxyl, C.sub.1-6alkyloxycarbonyl, or --C(=Z)Ar.sup.2; and the other one of R.sup.2a and R.sup.3a is hydrogen; in case R.sup.2a is different from hydrogen then R.sup.2b is hydrogen, C.sub.1-6alkyl or halogen and R.sup.3b is hydrogen; in case R.sup.3a is different from hydrogen then R.sup.3b is hydrogen, C.sub.1-6alkyl or halogen and R.sup.2b is hydrogen. It further concerns the preparation thereof and compositions comprising these compounds, as well as the use thereof as a medicine.